Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia

Carson, W.; McQuade, Robert D.; Saha, A.R.; Torbeyns, A.; Stock, E.

doi:10.1016/s0924-977x(02)80404-7

Cited by 10 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from two studies (18,45,58,68) were used to evaluate the longer-term (26 and 52 weeks) efficacy of aripiprazole. In a placebo-controlled study of 310 outpatients with chronic, stable schizophrenia, Carson et al (18) examined the effects of aripiprazole treatment over a 26 week period.…”

Section: Schizophrenia and Related Disordersmentioning

confidence: 99%

“…In a placebo-controlled study of 310 outpatients with chronic, stable schizophrenia, Carson et al (18) examined the effects of aripiprazole treatment over a 26 week period. Compared with placebo, aripiprazole (15 mg/day) was significantly more effective in increasing time-to-relapse, as well as in reducing the number of relapses and improving PANSS total scores and PANSS positive subscale scores.…”

Section: Schizophrenia and Related Disordersmentioning

confidence: 99%

See 1 more Smart Citation

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

2004

View full text Add to dashboard Cite

Aripiprazole (Abilify ® ) is an atypical antipsychotic drug that has been recently introduced for clinical use in the treatment of schizophrenia. Aripiprazole has a unique pharmacologic profile that includes partial agonism at several G-protein coupled receptors (GPCRs) [especially dopamine (D 2 ) and 5-HT 1A ] and antagonistic action at others (especially 5-HT 2A ). Clinical trials indicate that aripiprazole is effective in treating the positive and negative symptoms of schizophrenia. In short-term studies rapid onset of action (within one week) has been demonstrated. Preliminary data indicate that aripiprazole may also be effective in the treatment of manic symptoms of bipolar disorder. At recommended doses, aripiprazole appears to be safe and well tolerated in most adult patients with schizophrenia and schizoaffective disorder. There is only limited information available on the use of aripiprazole in children and adolescents, and pilot data suggest that a revised dosing strategy, based on weight, is indicated in this population. In the long-term studies, the use of aripiprazole was associated with continued efficacy, good compliance and increased time-to-relapse.Aripiprazole represents the first functionally selective atypical antipsychotic drug.

show abstract

Section: Schizophrenia and Related Disordersmentioning

confidence: 99%

Section: Schizophrenia and Related Disordersmentioning

confidence: 99%

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

2004

View full text Add to dashboard Cite

show abstract

“…Two studies have been completed to determine long-term maintenance and relapse prevention with aripiprazole. 21,22 The first was a 52-week, double-blind comparison study evaluating aripiprazole 30 mg versus haloperidol 10 mg (2:1 enrollment) for long-term maintenance of effect. 21 All 1294 patients enrolled had a DSM-IV diagnosis of schizophrenia with acute exacerbation and history of prior antipsychotic response and were considered moderately ill, with a baseline PANSS total score of 95 (mean).…”

Section: Clinical Trialsmentioning

confidence: 99%

Aripiprazole: A New Atypical Antipsychotic Drug

Bowles

Levin

2003

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…Data from pivotal clinical trials with aripiprazole demonstrate that aripiprazole is effective in the treatment of acute schizophrenia and in reducing relapse among individuals with stable, chronic schizophrenia [50,52,53]. Although data from clinical trials suggest that aripiprazole combines efficacy with an apparently benign adverse effect profile, more information is needed in a larger, "real world" population to more fully understand potential benefits and risks of aripiprazole therapy.…”

Section: Aripiprazolementioning

confidence: 99%

“…In the area of acute mania, aripiprazole has been superior to placebo [53]. A double-blind, placebo-controlled 3-week trial involving 262 patients with acute mania compared response on aripiprazole monotherapy (30 mg per day with option to decrease to 15 mg per day) with placebo.…”

Section: Aripiprazole In Mood and Anxiety Disordersmentioning

confidence: 99%

Treatment for mood and anxiety disorders: Quetiapine and aripiprazole

Sajatovic

2003

Curr Psychiatry Rep

View full text Add to dashboard Cite

Atypical antipsychotic agents have a broad range of therapeutic efficacy, a relatively low incidence of causing extrapyramidal adverse effects, and a low tardive dyskinesia profile. This has led to very rapid growth in the use of these compounds as broad-spectrum psychotropic agents, and it has been reported that more than 70% of prescriptions for atypical antipsychotic medications are being used for conditions other than schizophrenia. In the area of bipolar disorder, in particular, atypical antipsychotic agents appear to positively affect illness outcome, and are considered potential first-line treatment agents. Quetiapine was approved by the US Food and Drug Administration in 1997, and is currently marketed in the US to treat schizophrenia. Aripiprazole was recently approved for the treatment of schizophrenia by the US Food and Drug Administration in late 2002, and is being used increasingly in clinical settings. Recent reports suggest that quetiapine and aripiprazole are valuable additions to the psychotropic armamentarium for the treatment of mood and anxiety disorders. Data from clinical trials and clinical reports are discussed herewith.

show abstract

Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia

Cited by 10 publications

References 0 publications

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

Aripiprazole: A New Atypical Antipsychotic Drug

Treatment for mood and anxiety disorders: Quetiapine and aripiprazole

Contact Info

Product

Resources

About